Cargando…
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol
INTRODUCTION: Chimeric antigen receptor (CAR) T cells spark hope for patients with CD19+ B cell neoplasia, including relapsed or refractory (r/r) acute lymphoblastic leukaemia (ALL) or r/r non-Hodgkin’s lymphoma (NHL). Published studies have mostly used second-generation CARs with 4-1BB or CD28 as c...
Autores principales: | Schubert, Maria-Luisa, Schmitt, Anita, Sellner, Leopold, Neuber, Brigitte, Kunz, Joachim, Wuchter, Patrick, Kunz, Alexander, Gern, Ulrike, Michels, Birgit, Hofmann, Susanne, Hückelhoven-Krauss, Angela, Kulozik, Andreas, Ho, Anthony D., Müller-Tidow, Carsten, Dreger, Peter, Schmitt, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530404/ https://www.ncbi.nlm.nih.gov/pubmed/31110096 http://dx.doi.org/10.1136/bmjopen-2018-026644 |
Ejemplares similares
-
Impact of serum-free media on the expansion and functionality of CD19.CAR T-cells
por: Eberhardt, Franziska, et al.
Publicado: (2023) -
Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
por: Tang, Xiao-Yi, et al.
Publicado: (2016) -
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
por: George, Philip, et al.
Publicado: (2020) -
Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR
por: Schanda, Nicola, et al.
Publicado: (2021) -
Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I–II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21)
por: Sakaguchi, Hirotoshi, et al.
Publicado: (2023)